drugset / Trial / NCT00954278
Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the number of patients with advanced, relapsed non-small cell lung cancer who can tolerate dose escalation sorafenib from 400 mg twice daily to either 600 mg twice daily or 800 mg twice daily. Safety and tolerability of sorafenib will also be examined.
Timeline
- Start
- 2009-07-28
- Primary completion
- 2015-12-23
- Completion
- 2015-12-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 400 mg | Oral |
| Subject | Sorafenib | Small molecule | 600 mg | Oral |
| Subject | Sorafenib | Small molecule | 800 mg | Oral |